You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Transdermal Delivery of Buprenorphine Prodrugs

    SBC: ALLTRANZ, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently buprenorphine (BUP) is used in the treatment of opioid abuse and for pain management. It can also be used improperly and abused as an opioid. In the United States, buprenorphine is marketed in sublingual and injectable forms. While the drug provides effective treatment, these forms of drug delivery are not desirable because of their peak plasma level ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to optimize the flow of blood and oxygen to tissues. Increasing the bioavailability of NO should provide therapeutic benefit in the treatment of many diseases ascribed to insufficient NO bioavailability. A ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs and tissues for transplant in attempts to increase the supply of donor organs acceptable for transpl ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I gran ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Apyrase to treat ischemia/reperfusion injury during lung transplantation

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Developing an Evidence-Based Intervention Planning System for Obesity Prevention

    SBC: TRANSTRIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): To increase the effectiveness of chronic disease prevention and health promotion interventions, researchers and practitioners must work collaboratively to ensure that evidence-based approaches are translated into publicly accessible tools and resources. To disseminate evidence-based intervention strategies, it is essential to summarize the associated processes, ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. A Therapeutic Agent for Radiation-induced Lung Fibrosis

    SBC: AUXAGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and excessive deposition of extracellular matrix proteins (ECM) in lung parenchyma. Globally, five million people are affected by lung fibrosis. In the U.S. alone, 200,000 suffer from this disease. Of these m ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Exosomal microRNA profiles as diagnostic biomarkers of ovarian cancer

    SBC: TEKSHIFA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Detection of ovarian cancer at Stage I results in 5-year survivals of greater than 90%; however, only 23% of ovarian cancers are diagnosed early, with 67% being diagnosed with metastatic disease. Thus, new markers are being sought to accurate identify patients with ovarian cancer, particularly in early stage. Emerging evidence suggests the potential involvement ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Active Distributed Electrode Array Network for Electrical Stimulation Therapy

    SBC: CUSTOMKYNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Transcutaneous electrical stimulation applications involving high numbers of stimulated muscles have been an area of growing interest in recent years. customKYnetics has been approached in recent months by research groups and stimulation application developers requesting high channel count stimulation devices for use in their spinal cord injury rehabilitation ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacologic treatment of thromboembolism

    SBC: EVAS THERAPEUTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis. The limitations of currently approved anticoagulant drugs have prompted the search for new anticoagulants with better pharmacological profiles. EVAS Therapeutics, LLC ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government